MCP-1-CCR2-M2巨细胞轴有助于扩散大B细胞淋巴瘤的进展,并抑制抗瘤免疫反应
Zhao-Feng Wen1,2,3, Qi-Tang Huang1,2,4, Yang-Yang Wang1
1Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Scientific reports
|August 8, 2025
概括
用CCR2抗剂向MCP-1/CCR2轴有效地抑制扩散性大B细胞淋巴瘤 (DLBCL) 的进展,通过抑制原瘤的M2巨细胞极化和增强抗瘤T细胞反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种具有有限治疗选择的侵袭性癌症.
- MCP-1/CCR2轴对单细胞招募和巨细胞两极分化至关重要,这些过程与癌症进展有关.
研究的目的:
- 研究DLBCL中准MCP-1/CCR2-巨轴的治疗潜力.
- 在DLBCL患者中评估MCP-1,CD68,CD163和CD14+CCR2+单细胞的预后意义.
主要方法:
- 免疫组织化学和与酶相关的免疫吸收定位/流动细胞计用于分析患者的组织和血液样本.
- 实验室细胞培养和体内小鼠模型被用于评估CCR2抗剂阻塞的影响.
- 在MCP-1/CCR2轴抑制后,评估了巨细胞极化和T细胞反应.
主要成果:
- 在DLBCL患者中,增加的MCP-1,CD68,CD163表达和增加的CD14+CCR2+单细胞与更差的预后相关.
- 治疗CCR2抗剂有效地阻断了MCP-1/CCR2轴,减少了原发瘤的M2巨细胞两极分化.
- 治疗还促进了CD8+T细胞扩张,并在体内显著抑制了瘤生长.
结论:
- 在DLBCL进展中,MCP-1/CCR2-M2巨细胞极化轴起着至关重要的作用.
- 针对MCP-1/CCR2轴是DLBCL的一个有希望的治疗策略,具有临床转化潜力.
更多相关视频
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
7.6K
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
11.6K
相关概念视频
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Cell-mediated Immune Responses
72.5K
Overview
72.5K
The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
B Cell Activation and Differentiation
5.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
5.6K
